Corcoran, Ryan B. http://orcid.org/0000-0001-8173-5778
Article History
First Online: 24 August 2023
Competing interests
: R.B.C. has received consulting or speaking fees from Abbvie, Amgen, Array Biopharma/Pfizer, Asana Biosciences, Astex Pharmaceuticals, Astellas, Avidity Biosciences, BMS, C4 Therapeutics, Chugai, Cogent Biosciences, Daiichi-Sankyo Elicio, Erasca, Fog Pharma, Genentech, Guardant Health, Ipsen, Kinnate Biopharma, LOXO, Merrimack, Mirati Therapeutics, Natera, Navire, Nested Therapeutics, N-of-one/Qiagen, Novartis, nRichDx, Remix Therapeutics, Revolution Medicines, Roche, Syndax, Tango Therapeutics, Taiho and Theonys; holds equity in Avidity Biosciences, C4 Therapeutics, Cogent Biosciences, Erasca, Kinnate Biopharma, Interline Therapeutics, Nested Therapeutics, nRichDx, Remix Therapeutics, Revolution Medicines and Theonys; is a co-founder, equity holder and board member of Alterome Therapeutics and Sidewinder Therapeutics; and has received research funding from Asana, AstraZeneca, Invitae, Lilly, Novartis and Pfizer.